ImmunoCellular Therapeutics, Ltd. is a clinical-stage biotechnology company that is focused on developing new immune-based products to treat and diagnose cancer. Designed to harness both arms of the native immune system, our pipeline includes both active immunotherapies and patented monoclonal antibodies. Our active immunotherapies target not only regular tumor cells, but also the cancer stem cells believed to cause cancer growth and recurrence. Our strategy is to become the first company focused primarily on the development of cancer stem cell therapeutics, while working with partners to develop and commercialize our broadly applicable monoclonal antibodies. We believe our promising clinical programs, strong intellectual property, proprietary discovery technology, high-profile partnerships, and experienced leadership will allow us to continue building value for our shareholders.

IMUC.OB

Last trade:

1.61

Day's change:

0.04

Trade date:

"2/3/2012"

Trade time:

"3:59pm"

Opening:

1.63

Day's Range:

1.60 - 1.69

Volume:

143685